COMMUNIQUÉS West-GlobeNewswire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06/08/2018 - 22:50

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]

Syneos Health Announces Secondary Offering of Common Stock

06/08/2018 - 22:33

RALEIGH, N.C., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), a leading biopharmaceutical solutions organization combining a CRO (Contract Research Organization [...]

Antares Pharma Appoints Dr. James Tursi Executive Vice President, Head of Research & Development, Chief Medical Officer

06/08/2018 - 22:30

EWING, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of James P. Tursi M.D. to the position of Executive Vice President, Head of Research & Development, [...]

AMAG Pharmaceuticals Completes Divestiture of Cord Blood Registry®

06/08/2018 - 22:30

WALTHAM, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced it has closed the previously announced divestiture of Cord Blood Registry (CBR®) to GI Partners, a private [...]

Zogenix Provides Corporate Update and Reports Second Quarter Financial Results

06/08/2018 - 22:26

Reported positive top-line results from second pivotal Phase 3 trial of ZX008 in patients with Dravet syndrome, Study 1504 Submission of U.S. and EU regulatory filings for ZX008 in Dravet syndrome anticipated by year- [...]

NeoGenomics Announces Proposed Public Offering of Common Stock

06/08/2018 - 22:19

FT. MYERS, Fla., Aug. 06, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has commenced an underwritten public offering of [...]

VBI Vaccines to Present at the Canaccord Genuity 38th Annual Growth Conference

06/08/2018 - 22:15

CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, [...]

Neon Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights

06/08/2018 - 22:15

– Successfully completed initial public offering, raising $100 million in gross proceeds – – Significant progress across platform and portfolio of vaccine and T-cell programs – – Enrollment completed for NEO-PV-01 for [...]

Fulgent Genetics Reports Second Quarter 2018 Financial Results

06/08/2018 - 22:05

Second Quarter 2018 Results : Revenue totals $5.4 million, growing 16% year over year and 16% sequentially Billable tests delivered total 5,700, growing 47% year over year and 23% sequentially GAAP and non-GAAP gross [...]

Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06/08/2018 - 22:05

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent [...]

Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update

06/08/2018 - 22:05

– Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at ESMO 2018 – – Startup activities initiated for upcoming registration-directed trial of [...]

Akcea Reports Financial Results and Highlights for Second Quarter 2018

06/08/2018 - 22:05

TEGSEDI™ (inotersen) Approved in European Union $382 million to fund the company through key milestones in 2019 Conference Call Webcast Monday, August 6, 4:30 p.m. ET at www.akceatx.com CAMBRIDGE, Mass., Aug. 06, 2018 ( [...]

Editas Medicine Announces Second Quarter 2018 Results and Update

06/08/2018 - 22:05

Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States Plan to file EDIT-101 Investigational New Drug [...]

Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance

06/08/2018 - 22:05

Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care [...]

Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full

06/08/2018 - 22:05

SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic [...]

Quotient Limited Reports Senior Note Issuance and Warrant Cash Inflows and updates on MosaiQ Development and First Quarter Fiscal 2019 Financial Results

06/08/2018 - 22:05

$48.8 million of proceeds from warrant exercises received through July 31 $36 million of additional senior notes issued and funded in June Initial SDS microarray verification and validation started Record reagent [...]

Gemphire Provides Update On Development of Gemcabene

06/08/2018 - 22:01

FDA requests the Company provide additional data regarding the partial clinical hold Company continues Phase 2 development of gemcabene for NAFLD/NASH Company amends loan agreement with SVB to provide additional [...]

Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update

06/08/2018 - 22:01

- QBREXZA™ (glycopyrronium) cloth for the treatment of primary axillary hyperhidrosis approved in June 2018 - QBREXZA expected to be available nationwide in pharmacies beginning in October 2018 - Lebrikizumab Phase 2b [...]

Iovance Biotherapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

06/08/2018 - 22:01

- Company to Host Conference Call at 4:30pm ET Today - SAN CARLOS, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies [...]